



- (51) **International Patent Classification:**
G16H 20/00 (2018.01) *G16H 20/17* (2018.01)
- (21) **International Application Number:**
PCT/US2024/016386
- (22) **International Filing Date:**
19 February 2024 (19.02.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
PCT/US23/13418 20 February 2023 (20.02.2023) US
- (71) **Applicant (for US only): ROCHE DIABETES CARE, INC.** [US/US]; 9115 Hague Road, Indianapolis, Indiana 46250 (US).
- (71) **Applicant (for DE only): ROCHE DIABETES CARE GMBH** [DE/DE]; Sandhofer Strasse 116, 68305 Mannheim (DE).
- (71) **Applicant (for all designated States except DE, US): F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).
- (72) **Inventors: SCHWIRTLICH, Tim;** c/o Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim

(DE). **KREUZER, Andreas**; c/o Roche Diabetes Care GmbH, Sandhofer Strasse 116, 68305 Mannheim (DE). **MANOHAR, Chinmay**; c/o Roche Diabetes Care, Inc., 9115 Hague Road, Indianapolis, Indiana 46250 (US). **THAKRAR, Sanjay**; c/o Roche Diabetes Care, Inc., 9115 Hague Road, Indianapolis, Indiana 46250 (US). **RODENAS, Marina**; c/o Roche Diabetes Care France SAS, Avenue du Vercors, 38242 Meylan (FR).

- (74) **Agent: ALEXANDER, Ross E.**; 1717 Arch Street, Suite 3300, Philadelphia, Pennsylvania 19103 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV,

- (54) Title:** OPTIMIZATION AND PERSONALIZATION OF THERAPEUTIC PROTOCOLS




FIG. 1

(57) Abstract: Embodiments are described herein for optimizing and personalizing therapeutic protocols to treat a medical condition. An event of a therapeutic protocol may be determined. One or more triggering events may be detected for generating a notification associated with the event of the therapeutic protocol. The one or more triggering events may be determined to exceed a notification threshold indicating a level of confidence that a user will receive a notification transmitted in response to the one or more triggering events. The notification may be provided to a user to assist in treatment of a medical condition, such as a diabetic condition, in response to the detected triggering event associated with the event of the therapeutic protocol.

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))